{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:08:24Z","timestamp":1770163704285,"version":"3.49.0"},"reference-count":16,"publisher":"National Institute for Health and Care Research","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["NIHR128513"],"award-info":[{"award-number":["NIHR128513"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"\n Background<\/jats:title>\n People who inject drugs are disproportionately affected by hepatitis C virus. The emergence of direct-acting antiviral treatments for hepatitis C virus motivated England to achieve the World Health Organization\u2019s elimination target of decreasing hepatitis C virus incidence among people who inject drugs to <\u20052 per 100 person-years (\/100 person-years) by 2030. We determined whether existing testing and treatment strategies will reach this target in England, or whether improved strategies are needed and whether they are cost-effective.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n A dynamic hepatitis C virus transmission model among people who inject drugs was developed for four English regions. The model included the pathway from testing to treatment in prisons, drug treatment centres and other settings. Each pathway was parameterised using region-specific data, with yearly bio-behavioural surveys among people who inject drugs being used to parameterise and calibrate the model in a Bayesian framework. The model projected whether each region will reach the hepatitis C virus incidence target or what improvements (in testing and linkage to treatment) are needed from 2024 to achieve it.<\/jats:p>\n Hepatitis C virus care pathway costs were collated through interviews with practitioners and the published literature. The mean incremental cost-effectiveness ratio (per quality-adjusted life-year saved) was estimated for any \u2018improved\u2019 strategy that reached the incidence target compared to the baseline strategy. Incremental cost-effectiveness ratios were compared to a willingness-to-pay threshold of \u00a320,000\/quality-adjusted life-year saved over a 50-year time horizon (3.5% annual discount rate).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Across the four regions over 2016\u201322, an estimated 8831\u20139689 treatments occurred among 37,230 people who inject drugs, with the annual number treated increasing in prisons (7.8 times) and drug treatment centres (3.6 times). Model projections suggest that hepatitis C virus incidence among people who inject drugs has decreased across the regions by 56.1\u201385.4% (range of medians) over 2015\u201322, with incidence decreasing by 79.7\u201398.6% to 0.2\u20132.2\/100 person-years by 2030. The World Health Organization incidence target (<\u20052\/100 person-years) will be reached with >\u200580% probability in three regions and 40% probability in the other region. The probability of reaching the incidence target increases to >\u200565% in this region if screening is increased in drug treatment centres (80% screened annually) or prisons (75% of people get tested during their prison stay), with these screening strategies being cost-effective.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Numerous England regions may be on target to decrease hepatitis C virus incidence among people who inject drugs to <\u20052\/100 person-years. In regions that are not on target, further scale-up of testing in drug treatment centre or prison from 2024 could enable them to reach the World Health Organization elimination target and be cost-effective.<\/jats:p>\n <\/jats:sec>\n \n Limitations<\/jats:title>\n Projections were based on model estimations, which need to be confirmed with empirical data. Data uncertainties affected our model projections, including uncertainty in the number of people who inject drugs in each region and the number of treatments given to people who inject drugs in different settings. Sample sizes for the yearly bio-behavioural surveys among people who inject drugs were small, and so samples were pooled over multiple years. Testing rates among people who inject drugs could not be directly estimated because the sentinel surveillance had incomplete coverage and could not identify people who inject drugs; testing rates were estimated through model calibration.<\/jats:p>\n <\/jats:sec>\n \n Future work<\/jats:title>\n There is interest in understanding what scale-back in testing can occur after 2030 without resulting in a rebound in hepatitis C virus incidence, and in developing models for each devolved nation to determine their progress to World Health Organization hepatitis C virus elimination targets.<\/jats:p>\n <\/jats:sec>\n \n Funding<\/jats:title>\n This synopsis presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number NIHR128513.<\/jats:p>\n <\/jats:sec>","DOI":"10.3310\/gjpv1707","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T09:36:46Z","timestamp":1751881006000},"page":"1-14","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["The impact and cost-effectiveness of scaling up HCV treatment for achieving elimination among people who inject drugs in England: a synopsis including evidence synthesis and economic modelling"],"prefix":"10.3310","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0268-988X","authenticated-orcid":true,"given":"Zoe","family":"Ward","sequence":"first","affiliation":[{"name":"Population Health Sciences, Faculty of Health Sciences, University of Bristol, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8156-0146","authenticated-orcid":true,"given":"Ruth","family":"Simmons","sequence":"additional","affiliation":[{"name":"UK Health Security Agency (UKHSA), London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4340-9995","authenticated-orcid":true,"given":"Hannah","family":"Fraser","sequence":"additional","affiliation":[{"name":"Population Health Sciences, Faculty of Health Sciences, University of Bristol, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3462-2898","authenticated-orcid":true,"given":"Adam","family":"Trickey","sequence":"additional","affiliation":[{"name":"Population Health Sciences, Faculty of Health Sciences, University of Bristol, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3674-6045","authenticated-orcid":true,"given":"Joanna","family":"Kesten","sequence":"additional","affiliation":[{"name":"Population Health Sciences, Faculty of Health Sciences, University of Bristol, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9524-984X","authenticated-orcid":true,"given":"Andrew","family":"Gibson","sequence":"additional","affiliation":[{"name":"University of West of England, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3727-6708","authenticated-orcid":true,"given":"Leila","family":"Reid","sequence":"additional","affiliation":[{"name":"The Hepatitis C Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6763-8091","authenticated-orcid":true,"given":"Sean","family":"Cox","sequence":"additional","affiliation":[{"name":"The Hepatitis C Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6026-4351","authenticated-orcid":true,"given":"Fiona","family":"Gordon","sequence":"additional","affiliation":[{"name":"University Hospitals Bristol, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5638-2453","authenticated-orcid":true,"given":"Stuart","family":"McPherson","sequence":"additional","affiliation":[{"name":"Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9649-4444","authenticated-orcid":true,"given":"Stephen","family":"Ryder","sequence":"additional","affiliation":[{"name":"Nottingham University Hospitals NHS Trust, Nottingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0957-1018","authenticated-orcid":true,"given":"Francisco Javier","family":"Vilar","sequence":"additional","affiliation":[{"name":"Manchester University NHS Foundation Trust, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2510-9007","authenticated-orcid":true,"given":"Alec","family":"Miners","sequence":"additional","affiliation":[{"name":"London School of Hygiene and Tropical Medicine, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1331-387X","authenticated-orcid":true,"given":"Jack","family":"Williams","sequence":"additional","affiliation":[{"name":"London School of Hygiene and Tropical Medicine, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1223-5571","authenticated-orcid":true,"given":"Beatrice","family":"Emmanouil","sequence":"additional","affiliation":[{"name":"NHS England, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8632-9808","authenticated-orcid":true,"given":"Monica","family":"Desai","sequence":"additional","affiliation":[{"name":"UK Health Security Agency (UKHSA), London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0300-4950","authenticated-orcid":true,"given":"Laura","family":"Coughlan","sequence":"additional","affiliation":[{"name":"UK Health Security Agency (UKHSA), London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3190-7281","authenticated-orcid":true,"given":"Ross","family":"Harris","sequence":"additional","affiliation":[{"name":"UK Health Security Agency (UKHSA), London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3704-386X","authenticated-orcid":true,"given":"Graham","family":"R Foster","sequence":"additional","affiliation":[{"name":"NHS England, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9864-459X","authenticated-orcid":true,"given":"Matthew","family":"Hickman","sequence":"additional","affiliation":[{"name":"Population Health Sciences, Faculty of Health Sciences, University of Bristol, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3379-3118","authenticated-orcid":true,"given":"Sema","family":"Mandal","sequence":"additional","affiliation":[{"name":"UK Health Security Agency (UKHSA), London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8291-5890","authenticated-orcid":true,"given":"Peter","family":"Vickerman","sequence":"additional","affiliation":[{"name":"Population Health Sciences, Faculty of Health Sciences, University of Bristol, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6221","published-online":{"date-parts":[[2026,1]]},"reference":[{"key":"key2026020315331500_ref1-bib1","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S2468-1253(21)00471-4","article-title":"Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: a systematic review and meta-analysis","volume":"7","author":"Cunningham","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"key2026020315331500_ref2-bib2","doi-asserted-by":"crossref","first-page":"103917","DOI":"10.1016\/j.drugpo.2022.103917","article-title":"Interventions to enhance testing and linkage to treatment for hepatitis C infection for people who inject drugs: a systematic review and meta-analysis","volume":"111","author":"Cunningham","year":"2023","journal-title":"Int J Drug Policy"},{"key":"key2026020315331500_ref3-bib3","volume-title":"Hepatitis C in the UK 2023: Working to Eliminate Hepatitis C as a Public Health Threat","author":"UKHSA","year":"2023"},{"key":"key2026020315331500_ref4-bib4","volume-title":"Taking a Place-based Approach to Tackling Hepatitis in Prisons","author":"UKHSA","year":"2023"},{"key":"key2026020315331500_ref5-bib5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/jvh.13626","article-title":"Role of peer support in a hepatitis C elimination programme","volume":"29","author":"Jugnarain","year":"2022","journal-title":"J Viral Hepat"},{"key":"key2026020315331500_ref6-bib6","doi-asserted-by":"crossref","first-page":"102608","DOI":"10.1016\/j.drugpo.2019.102608","article-title":"Time matters: point of care screening and streamlined linkage to care dramatically improves hepatitis C treatment uptake in prisoners in England","volume":"75","author":"Mohamed","year":"2020","journal-title":"Int J Drug Policy"},{"key":"key2026020315331500_ref7-bib7","volume-title":"Hepatitis C Treatment Monitoring in England: Content, Completeness and Preliminary Findings from the Hepatitis C Patient Registry and Treatment Outcome System","author":"Harris","year":"2018"},{"key":"key2026020315331500_ref9-bib9","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/jvh.12844","article-title":"Establishing the cascade of care for hepatitis C in England-benchmarking to monitor impact of direct acting antivirals","volume":"25","author":"Simmons","year":"2018","journal-title":"J Viral Hepat"},{"key":"key2026020315331500_ref10-bib10","first-page":"1","article-title":"Impact and cost-effectiveness of scaling up HCV testing and treatment strategies for achieving HCV elimination among people who inject drugs in England: a mathematical modelling study","volume":"49","author":"Ward","year":"2025","journal-title":"Lancet Reg Health Eur"},{"key":"key2026020315331500_ref11-bib11","volume-title":"Hepatitis C: Operational Delivery Network (ODN) Profile Tool","author":"UKHSA","year":"2018"},{"key":"key2026020315331500_ref12-bib12","doi-asserted-by":"crossref","first-page":"v5","DOI":"10.1093\/jac\/dkz451","article-title":"The cost-effectiveness of an HCV outreach intervention for at-risk populations in London, UK","volume":"74","author":"Ward","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"key2026020315331500_ref13-bib13","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jhep.2012.11.004","article-title":"Decrease in health-related quality of life associated with awareness of hepatitis C virus infection among people who inject drugs in Scotland","volume":"58","author":"McDonald","year":"2013","journal-title":"J Hepatol"},{"key":"key2026020315331500_ref14-bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta11110","article-title":"Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation","volume":"11","author":"Shepherd","year":"2007","journal-title":"Health Technol Assess"},{"key":"key2026020315331500_ref15-bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta10210","article-title":"Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation","volume":"10","author":"Wright","year":"2006","journal-title":"Health Technol Assess"},{"key":"key2026020315331500_ref16-bib16","doi-asserted-by":"crossref","first-page":"e025192","DOI":"10.1136\/bmjopen-2018-025192","article-title":"Health-related quality of life and prevalence of six chronic diseases in homeless and housed people: a cross-sectional study in London and Birmingham, England","volume":"9","author":"Lewer","year":"2019","journal-title":"BMJ Open"},{"key":"key2026020315331500_ref17-bib17","volume-title":"Guide to the Methods of Technology Appraisal 2013 (PMG9)","author":"National Institute of Health and Care Excellence (NICE)","year":"2013"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2049890","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/sites\/journalslibrary\/files\/journal_data\/GJPV1707\/GJPV1707.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2049890","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T12:18:29Z","timestamp":1770121109000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/GJPV1707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":16,"alternative-id":["10.3310\/GJPV1707"],"URL":"https:\/\/doi.org\/10.3310\/gjpv1707","relation":{},"ISSN":["2046-4924"],"issn-type":[{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"01-2020","name":"contractual_start_date","label":"contractual_start_date","group":{"name":"article_history","label":"Article History"}},{"value":"02-2025","name":"editorial_review_begun","label":"editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"07-2025","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}